Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.
24/7 Wall St. on MSN3h
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback